The FDA granted Orphan Drug Designation for VGT-1849B, a development involving Vanda Pharmaceuticals.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted Orphan Drug Designation for VGT-1849B, a development involving Vanda Pharmaceuticals.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The FDA granted Rare Pediatric Disease Designation to Vanda's therapy.Sub-event
FDA granted Orphan Drug Designation for VGT-1849B for Vanda Pharmaceuticals.1 source
Keep exploring
The entities involved
- FDA
-
Vanda Pharmaceuticals (United States)
company in Washington D.C., United States
Nothing else this week.
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- The FDA identified deficiencies in a drug application submitted by Aquestive Therapeutics, Inc.
- FDA granted clearance for DVT treatment involving Penumbra, Inc.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- FDA provided guidance for HCW Biologics' IND application.
Coverage
Newest first; wire copies grouped- PR NewswireVanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera WASHINGTON, Aug. 28, 2025 /PRNewswire/ -- Van